These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 15578690)

  • 1. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.
    Lee L; Sudentas P; Donohue B; Asrican K; Worku A; Walker V; Sun Y; Schmidt K; Albert MS; El-Hashemite N; Lader AS; Onda H; Zhang H; Kwiatkowski DJ; Dabora SL
    Genes Chromosomes Cancer; 2005 Mar; 42(3):213-27. PubMed ID: 15578690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
    Lee L; Sudentas P; Dabora SL
    Genes Chromosomes Cancer; 2006 Oct; 45(10):933-44. PubMed ID: 16845661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
    Kenerson HL; Aicher LD; True LD; Yeung RS
    Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.
    Messina MP; Rauktys A; Lee L; Dabora SL
    BMC Pharmacol; 2007 Nov; 7():14. PubMed ID: 17986349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
    Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
    BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
    Kwiatkowski DJ; Manning BD
    Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.
    El-Hashemite N; Walker V; Zhang H; Kwiatkowski DJ
    Cancer Res; 2003 Sep; 63(17):5173-7. PubMed ID: 14500340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
    Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
    Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment.
    El-Hashemite N; Zhang H; Walker V; Hoffmeister KM; Kwiatkowski DJ
    Cancer Res; 2004 May; 64(10):3436-43. PubMed ID: 15150095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
    Nobukini T; Thomas G
    Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
    Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
    Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H; Dundon TA; Yeung RS
    Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
    Ma L; Teruya-Feldstein J; Bonner P; Bernardi R; Franz DN; Witte D; Cordon-Cardo C; Pandolfi PP
    Cancer Res; 2007 Aug; 67(15):7106-12. PubMed ID: 17671177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
    Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
    Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in neurobiology of Tuberous Sclerosis Complex.
    Napolioni V; Moavero R; Curatolo P
    Brain Dev; 2009 Feb; 31(2):104-13. PubMed ID: 19028034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
    Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
    Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
    Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
    Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
    Astrinidis A; Henske EP
    Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.